|
營收較上年下降10.61%；激光器件得益於新品推出及海外市場拓展，公司擬向全體股東每10股派發現金紅利1元（含稅），以資本公積金向全體股東每10股轉增1股。同比增長1.7 |
光算谷歌外链光算谷歌seo光算蜘蛛池光算蜘蛛池光算谷歌seo公司光算谷歌广告光算谷歌seo代运营光算谷歌seo光算谷歌外鏈光算谷歌推广光算蜘蛛池https://synapse.patsnap.com/article/exploring-ly500307-a-promising-therapeutic-approach-for-glioblastoma-treatmenthttps://synapse.patsnap.com/article/abbvie-finalizes-87-billion-acquisitionhttps://synapse.patsnap.com/drug/a7388e6032674bf18b0893a9cc01311ehttps://synapse.patsnap.com/article/what-is-64cu-dota-3-tyr-octreotate-used-forhttps://synapse.patsnap.com/article/what-is-docarpamine-used-forhttps://synapse.patsnap.com/article/what-is-donepezil-hydrochloride-used-forhttps://synapse.patsnap.com/drug/5adfc166fc8a432185936faa26788bbfhttps://synapse.patsnap.com/article/lillys-tirzepatide-reduces-diabetes-risk-study-showshttps://synapse.patsnap.com/article/sanofi-secures-first-cd38-approval-for-multiple-myelomahttps://synapse.patsnap.com/article/how-can-ai-predict-new-therapeutic-uses-for-approved-drugshttps://synapse.patsnap.com/article/regulatory-review-update-on-lecanemab-for-early-alzheimer%25E2%2580%2599s-in-the-euhttps://synapse.patsnap.com/article/intra-cellular-therapies-files-snda-for-caplyta%25C2%25AE-as-adjunctive-treatment-for-major-depressive-disorderhttps://synapse.patsnap.com/drug/15e9b335b94146f68051d261972d79a8https://synapse.patsnap.com/drug/49909bb15bcc4b699aca9a982c0d31bbhttps://synapse.patsnap.com/drug/36d2bbf44261492daac956e2db556fcchttps://synapse.patsnap.com/article/what-is-the-mechanism-of-chlorthalidonehttps://synapse.patsnap.com/drug/d8fea4a52cce46fba671f6ad04839355https://synapse.patsnap.com/drug/2b0630c7ec4546bab02406dee676e40bhttps://synapse.patsnap.com/article/what-are-prdx5-modulators-and-how-do-they-workhttps://synapse.patsnap.com/article/what-is-the-mechanism-of-schizophyllanhttps://synapse.patsnap.com/article/what-is-rizatriptan-benzoate-used-forhttps://synapse.patsnap.com/blog/palleon-pharma-presents-glimmer-01-findings-on-e-602-and-cemiplimab-for-solid-tumorshttps://synapse.patsnap.com/drug/d6094183e64b46a9927067d2eac09dbdhttps://synapse.patsnap.com/drug/8bf658c729544ff492d4d88eecb4d9bfhttps://synapse.patsnap.com/drug/954ea85360a241eabfc83de339fe55c1https://synapse.patsnap.com/article/coya-therapeutics-files-new-us-patents-for-coya-301-with-glp-1-receptor-agonistshttps://synapse.patsnap.com/drug/4e95a726020a437dac733c180c5abc87https://synapse.patsnap.com/blog/linnaeus-therapeutics-to-present-positive-lns8801-results-in-metastatic-melanoma-at-esmo-2024https://synapse.patsnap.com/drug/ac8d4639e7b84e5cad3a4b79b672a326https://synapse.patsnap.com/blog/adverum-biotechs-phase-2-luna-study-shows-promising-ixo-vec-results-for-wet-amd